

12-05-01

A
BOX/SEA

Please type a plus sign (+) inside this box ☐

Attorney Docket P3130R1C1
PATENT

11/15/01
11057 U.S. PTO

CERTIFICATION UNDER 37 CFR 1.10	
EL 895 375 467 US: Express Mail Number	November 15, 2001: Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION
Assistant Commissioner of Patents
Washington, D.C. 20231

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Avi J. Ashkenazi, San Mateo, CA
Kevin P. Baker, Darnestown, MD
David A. Botstein, Belmont, CA
Luc Desnoyers, San Francisco, CA
Dan L. Eaton, San Rafael, CA
Napoleone Ferrara, San Francisco, CA
Sherman Fong, Alameda, CA
Wei-Qiang Gao, Palo Alto, CA
Hanspeter Gerber, San Francisco, CA
Mary E. Gerritsen, San Mateo, CA
Audrey Goddard, San Francisco, CA
Paul J. Godowski, Burlingame, CA
Austin L. Gurney, Belmont, CA
Ivar J. Kljavin, Lafayette, CA
Jennie P. Mather, Millbrae, CA
Mary A. Napier, Hillsborough, CA
James Pan, Belmont, CA
Nicholas F. Paoni, Belmont, CA
Margaret Ann Roy, San Francisco, CA
Timothy A. Stewart, San Francisco, CA
Daniel Tumas, Orinda, CA
Colin K. Watanabe, Moraga, CA
P. Mickey Williams, Half Moon Bay, CA
William I. Wood, Hillsborough, CA
Zemin Zhang, Foster City, CA

Title: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS
ENCODING THE SAME

1. Type of Application

[] This application is for an original, non-provisional application.reference.

[] This is a non-provisional application claiming priority to provisional application no. __, filed __, the entire disclosure of which is hereby incorporated by

[X] This is a [X] continuation application claiming priority to application Serial Numbers: 60/056974 Filed 8/26/97; 60/059115 Filed 9/17/97; 60/059263 Filed 9/18/97; 60/059588 Filed 9/17/97; 60/062285 Filed 10/17/97; 60/062816 Filed 10/24/97; 60/063082 Filed 10/31/97; 60/063329 Filed 10/27/97; 60/063733 Filed 10/29/97; 60/066364 Filed 11/21/97; 60/066840 Filed 11/25/97; 60/069694 Filed 12/16/97; 60/074086 Filed 2/9/98; 60/074092 Filed 2/9/98; 60/079294 Filed 3/25/98; 60/081049 Filed 4/8/98; 60/095998 Filed 8/10/98; 60/097000 Filed 8/18/98; 60/099601 Filed 9/9/98; 60/099803 Filed 9/10/98; 60/099811 Filed 9/10/98; 60/099812 Filed 9/10/98; 60/100858 Filed 9/17/98; 60/101922 Filed 9/24/98; 60/106032 Filed 10/28/98; 60/109304 Filed 11/20/98; 60/125778 Filed 3/23/99; 60/139695 Filed 6/15/99; 60/145070 Filed 7/20/99; 60/145698 Filed 7/26/99; 60/149396 Filed 8/17/99; 60/169495 Filed 12/7/99; 08/918874 Filed 8/26/97, now abandoned; 08/933821 Filed 9/19/97, now U.S. Patent No. 5,972,338 Issued 10/26/99; 08/960507 Filed 10/29/97, now U.S. Patent No. 6,057,435 Issued 5/2/00; 09/114844 Filed 7/14/98; 09/136801 Filed 8/19/98; 09/136804 Filed 8/19/98, now abandoned; 09/136828 Filed 8/19/98; 09/158342 Filed 9/21/98, now abandoned; 09/180997 Filed 9/10/98, now abandoned; 09/202088 Filed 12/8/98; 09/254311 Filed 3/3/99, now abandoned; 09/254460 Filed 3/9/99, now abandoned; 09/254465 Filed 3/5/99; 09/284663 Filed 4/15/99; 09/332928 Filed 6/14/99; 09/332929 Filed 6/14/99; 09/333075 Filed 6/14/99; 09/333077 Filed 6/14/99; 09/380137 Filed 8/25/99; 09/380138 Filed 8/25/99, now abandoned; 09/380139 Filed 8/25/99; 09/403296 Filed 10/18/99, now abandoned; 09/403297 Filed 10/18/99, now abandoned; 09/423741 Filed 11/10/99, now abandoned; 09/423844 Filed 11/12/99, now abandoned; 09/522342 Filed 3/9/00; 09/548815 Filed 4/13/00; 09/664610 Filed 9/18/00, now abandoned; 09/665350 Filed 9/18/00; 09/709238 Filed 11/8/00; 09/767609 Filed 1/22/01; 09/802706 Filed 3/9/01; 09/808689 Filed 3/14/01, now abandoned; 09/866028 Filed 5/25/01; 09/870574 Filed 5/30/01; 09/872035 Filed 6/1/01; 09/886342 Filed 6/19/01; PCT/US98/14552 Filed 7/14/98; PCT/US98/18824 Filed 9/10/98, now abandoned; PCT/US98/19093 Filed 9/14/98; PCT/US98/19330 Filed 9/16/98; PCT/US98/19437 Filed 9/17/98, now abandoned; PCT/US98/24855 Filed 11/20/98; PCT/US98/25108 Filed 12/1/98; PCT/US98/25190 Filed 11/25/98; PCT/US99/05028 Filed 3/8/99; PCT/US99/12252 Filed 6/2/99; PCT/US99/20111 Filed 9/1/99; PCT/US99/20594 Filed 9/8/99; PCT/US99/21090 Filed 9/15/99; PCT/US99/21547 Filed 9/15/99; PCT/US99/28301 Filed 12/1/99; PCT/US99/28313 Filed 11/30/99; PCT/US99/28565 Filed 12/2/99; PCT/US99/30999 Filed 12/20/99; PCT/US00/00219 Filed 1/5/00; PCT/US00/04341 Filed 2/18/00; PCT/US00/04342 Filed 2/18/00; PCT/US00/04414 Filed 2/22/00; PCT/US00/05601 Filed 3/1/00; PCT/US00/05841 Filed 3/2/00; PCT/US00/06471 Filed 3/9/00; PCT/US00/07377 Filed 3/20/00; PCT/US00/08439 Filed 3/30/00; PCT/US00/13358 Filed 5/15/00; PCT/US00/13705 Filed 5/17/00; PCT/US00/14042 Filed 5/22/00; PCT/US00/14941 Filed 5/30/00; PCT/US00/15264 Filed 6/2/00; PCT/US00/22031 Filed 8/11/00; PCT/US00/23328 Filed 8/24/00; PCT/US00/23522 Filed 8/23/00; PCT/US00/32678 Filed 12/1/00; PCT/US01/06520 Filed 2/28/01; PCT/US01/17443 Filed 5/30/01; PCT/US01/17800 Filed 6/1/01; PCT/US01/19692 Filed 6/20/01; PCT/US01/21066 Filed 6/29/01; PCT/US01/21735 Filed 7/9/01, the entire disclosures of which are hereby incorporated by reference.

2. **Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Non-provisional)**

159 pages of specification
8 pages of claims
1 page(s) of abstract
75 sheet(s) of drawings
☒ formal ☐ informal

3. **Declaration or Oath**

(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)
X An executed declaration of the inventor(s) ☒ is enclosed ☐ will follow.

(for Cont./Div. where inventorship is the same or inventor(s) being deleted)
 A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

(for Cont./Div. where inventor(s) being deleted)
 A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

4. **Assignment**

(for new and CIP applications)
X An Assignment of the invention to GENENTECH, INC. ☒ is enclosed with attached Recordation Form Cover Sheet ☐ will follow.

(for cont./div.)
 The prior application is assigned of record to Genentech, Inc.

5. **Amendments (for continuation and divisional applications)**

 Cancel in this application original claims of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

X A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

100394

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$710.00
Total Claims	49	- 20 =	29	X \$18.00	\$580.00
Independent Claims	23	- 3 =	20	X \$80.00	\$1,600.00
<u>X</u> Multiple dependent claim(s), if any				+ \$270.00	\$270.00
Filing Fee Calculation					\$3,160.00

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$3,160.00. **A duplicate copy of this transmittal is enclosed.**

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this sheet is enclosed.**

9. Additional Papers Enclosed

- ☐ Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- ☒ Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- ☐ A new Power of Attorney or authorization of agent.
- ☒ Other: Postcard.

10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

*[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]*

- _____ A petition, fee and/or response has been filed to extend the term in the pending prior application until
- _____ A copy of the petition for extension of time in the **prior** application is attached.

10691166001

11. Correspondence Address:

X Address all future communications to:

Attn: Ginger R. Dreger, Esq.
Knobbe, Martens, Olson & Bear
201 California Street #1150
San Francisco, CA 94111-3335
Telephone: 415-954-4114
Email: gdreger@kmob.com

Respectfully submitted,
GENENTECH, INC.

By: Elizabeth M. Barnes
Elizabeth M. Barnes, Ph.D.
Reg. No. 35,059
Telephone No. (650) 225-4563

Date: November 15, 2001



09157

PATENT TRADEMARK OFFICE

09157